Patents by Inventor Ashwini Hinge

Ashwini Hinge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for preservation of human hematopoietic stem or progenitor cells
    Patent number: 8859282
    Abstract: Maintenance of quiescent hematopoietic stem and progenitor cells (HSPC) in culture without the addition of exogenous growth factors is an important aspect in clinical hematology. A recent report described the ability of Flt3 receptor-interacting lectin (FRIL) in the maintenance of cord blood (CB) derived progenitors in vitro. Since FRIL is a mannose binding lectin, the effectiveness of four such lectins of well-characterized specificities on the preservation of HSPC of CB origin have been examined. The HSPC preservation activity of lectins was assessed by in vitro colony forming unit (CFU) and long-term culture initiating cell (LTC-IC) assays. It was found that all four lectins had a HSPC preservation activity at least up to 30 days in culture without addition of exogenous growth factors. The results indicate that use of such lectins may provide a cost effective method of HSPC maintenance for clinical use.
    Type: Grant
    Filed: June 27, 2006
    Date of Patent: October 14, 2014
    Assignees: Department of Biotechnology, Indian Institute of Sciences
    Inventors: Vaijayanti P. Kale, Lalita S. Limaye, Ashwini Hinge, Avadhesha Surolia
  • Method for Preservation of Human Hematopoietic Stem or Progenitor Cells
    Publication number: 20090305325
    Abstract: Maintenance of quiescent hematopoietic stem and progenitor cells (HSPC) in culture without the addition of exogenous growth factors is an important aspect in clinical hematology. A recent report described the ability of Flt3 receptor-interacting lectin (FRIL) in the maintenance of cord blood (CB) derived progenitors in vitro. Since FRIL is a mannose binding lectin, the effectiveness of four such lectins of well-characterized specificities on the preservation of HSPC of CB origin have been examined. The HSPC preservation activity of lectins was assessed by in vitro colony forming unit (CFU) and long-term culture initiating cell (LTC-IC) assays. It was found that all four lectins had a HSPC preservation activity at least up to 30 days in culture without addition of exogenous growth factors. The results indicate that use of such lectins may provide a cost effective method of HSPC maintenance for clinical use.
    Type: Application
    Filed: June 27, 2006
    Publication date: December 10, 2009
    Applicants: DEPARTMENT OF BIOTECHNOLOGY, NATIONAL CENTRE FOR CELL SCIENCE, INDIAN INSTITUTE OF SCIENCES
    Inventors: Vaijayanti P. Kale, Lalita S. Limaye, Ashwini Hinge, Avadhesha Surolia